Wellman Center Lecture Series

October 10, 2017

Massachusetts General Hospital
50 Blossom Street, 1st Floor, Thier Conference Room
Boston, MA 02114

"Single-agent Chemophototherapy with PoP Liposomes"

Jonathan Lovell, PhD
Associate Professor of Biomedical Engineering
State University of New York (SUNY) at Buffalo
Buffalo, NY

Jonathan F. Lovell is an Associate Professor of Biomedical Engineering at the State University of New York at Buffalo. Dr. Lovell's work has been recognized with several awards including the NIH Early Independence Award (2013), the Biomedical Engineering Society Young Investigator Award (2015), and a NSF CAREER award (2016). Dr. Lovell's research interests include developing clinically translatable nanoplatforms to address unmet clinical needs. Dr. Lovell has co-authored over 80 peer reviewed manuscripts and 10 patent applications.

Porphyrin-phospholipid (PoP) conjugates can be incorporated into conventional liposomes and behave like a conventional phospholipids in large part with two exceptions: (1) Exposure to near infrared (NIR) light can trigger rapid permeabilization of the bilayer, depending on the liposome formulation. (2) PoP inclusion allows straightforward NIR optical fluorescence imaging of PoP distribution and also provides a convenient handle for seamless copper-64 labeling for positron emission tomography. Liposomes have been developed that can release anti-cancer drugs in response to NIR laser irradiation, leading to enhanced drug deposition in irradiated tumors. Inclusion of 2 molar % PoP imparted optimal near infrared (NIR) light-triggered release of doxorubicin (Dox) from conventional sterically stabilized stealth liposomes. Dox in stealth PoP liposomes had a circulation half-life in mice of 21.9 hours and was stable in storage for months. Following intravenous injection and NIR tumor irradiation, Dox deposition increases by about an order of magnitude in various subcutaneous and orthotopic tumor models. To our knowledge, Dox-loaded stealth PoP liposomes represent the first reported long-circulating nanoparticle capable of light-triggered drug release. This talk will discuss recent data and logistics of such a single agent chemophototherapy paradigm. This approach presents opportunities to use a single treatment to potently treat local disease while simultaneously providing systemic treatment for advanced cancers.